Sunday September 22, 2019

Fish Oil Pills have Little or No Effect on Risk of Type 2 Diabetes

According to the team from University of East Anglia (UEA), omega 3 supplements offer no benefit

0
//
Fish Oil, Pills, Diabetes
Increased consumption of omega 3 fats is widely promoted because of a common belief that it will protect against, or even reverse, conditions such as diabetes. Pixabay

If you are popping fish oil supplements to protect yourself against diabetes, you may be mistaken. According to the researchers, Omega-3 fats have little or no effect on risk of Type 2 diabetes.

Increased consumption of omega 3 fats is widely promoted because of a common belief that it will protect against, or even reverse, conditions such as diabetes.

According to the team from University of East Anglia (UEA), omega 3 supplements offer no benefit.

“Our previous research has shown that long-chain omega 3 supplements, including fish oils, do not protect against conditions such as heart disease, stroke or death. This review shows that they do not prevent or treat diabetes either,” said Dr Lee Hooper, from UEA’s Norwich Medical School.

Fish Oil, Pills, Diabetes
If you are popping fish oil supplements to protect yourself against diabetes, you may be mistaken. Pixabay

“Omega-3 supplements should not be encouraged for diabetes prevention or treatment,” he added.

If people do choose to take supplementary fish oil capsules to treat or prevent diabetes, or to reduce levels of triglycerides in their blood, then they should use doses of less than 4.4 grams per day to avoid possible negative outcomes.

“The most trustworthy studies consistently showed little or no effect of long-chain omega 3 fats on diabetes,” said the paper.

Omega 3 is a type of fat. Small amounts are essential for good health and can be found in the food that we eat. Omega 3 fats are also readily available as over-the-counter supplements and they are widely bought and used.

Also Read- Acupressure can Improve Chronic Pain Symptoms in Lower Back

The research team assessed the effects of long-chain omega-3 fats, ALA, omega-6 and polyunsaturated fatty acids (PUFAs) – taken as supplementary capsules, or via enriched or naturally rich foods.

Participants included men and women, some healthy and others with existing diabetes, from North America, South America, Europe, Australia and Asia, in studies published from the 1960s until 2018.

Participants were randomly assigned to increase their polyunsaturated fats or to maintain their usual intake for at least six months.

There was clearly no effect of increasing long-chain omega-3 fats on diabetes, but there was insufficient information from trials of ALA, omega-6 or total polyunsaturated fats to assess either protective or harmful effects.

Fish Oil, Pills, Diabetes
According to the researchers, Omega-3 fats have little or no effect on risk of Type 2 diabetes. Pixabay

The results show that increasing long-chain omega-3 had little or no effect on diabetes diagnosis or glucose metabolism, but high doses, at levels found in some supplements, could worsen glucose metabolism.

“Oily fish can be a very nutritious food as part of a balanced diet, but we did not find enough trials that encouraged participants to eat more oily fish to know whether it is useful in preventing diabetes or improving glucose metabolism,” said Dr Julii Brainard from Norwich Medical School.

Also Read- Vodafone Emerges as the Fastest 4G Network in Delhi

“Future trials need to measure and assess baseline omega-3 intakes, and assess effects of eating more oily fish — not just supplements,” she added. (IANS)

Next Story

Diabetes Medication to Reduce Heart Disease Shows Promise: Researchers

The results are applicable primarily to dapagliflozin, which was the predominant SGLT2 inhibitor used in Scandinavia during the study period

0
diabetes
Diabetes is the ninth leading cause of death in women and claims 2.1 million female lives every year, more so than men. Pixabay

Researchers, including one of an Indian-origin, have shed light on how a class of medications that help regulate blood sugar for patients with Type 2 diabetes can also protect from heart disease.

The findings published in the journal Cell Metabolism, focus on the effect of diabetes medication — empagliflozin — on cell repair in blood vessels and the resulting risks of heart disease.

Empagliflozin is a medication that falls under a category of drugs called SGLT2 inhibitors, which lower blood sugar.

“We have seen large-scale clinical trials giving us clear evidence that SGLT2 inhibitors can also protect our patients who have diabetes from heart disease,” said Indian-origin researcher and study author Subodh Verma from St. Michael’s Hospital in Canada.

The research suggests that circulating progenitor cells — which are found in the bone marrow and play a role in heart health — along with inflammatory cells are regulated with this diabetes medication.

For patients who have diabetes are at the risk of heart disease, such medications may provide heart protection by relieving damaged cells that would otherwise perpetuate heart disease by causing faulty vessel repair.

Diabetes
According to the researchers, these novel findings may provide the basis for new therapies for patients who have heart disease complicated by diabetes. Pixabay

Using blood samples from the EMPA-HEART CardioLink-6 Trial, the research team was able to show that in diabetes, regenerative progenitor cells were reduced.

Patients who took empagliflozin, however, these progenitor cells were restored later.

“We found that in people with diabetes, not only were beneficial progenitor cells increased but we saw indications of reduced inflammation and oxidative stress, which can also contribute to cardiovascular disease,” said David Hess, Associate Professor at Western University.

According to the researchers, these novel findings may provide the basis for new therapies for patients who have heart disease complicated by diabetes.

Also Read: Social Networking Giant Facebook Plans Test to Let Users Hide ‘Like’ Counts

Earlier a research from Karolinska Institute in Sweden said that the new type of drugs for type 2 diabetes — SGLT2 inhibitors — are associated with a reduced risk of heart failure by 34 per cent.

The results are applicable primarily to dapagliflozin, which was the predominant SGLT2 inhibitor used in Scandinavia during the study period. (IANS)